Immunocore Reports Encouraging Early Survival Results for Dual Drug Combination in Advanced Eye Melanoma

Early data show 70% two-year survival with brenetafusp plus KIMMTRAK in first-line metastatic uveal melanoma. Median OS not reached after 29 months.